Kanoot Jaruthamsophon

6PUBLICATIONS
41CO-AUTHORS
Disease surveillanceEpigenetics (incl. genome methylation and epigenomics)Catalysis and mechanisms of reactionsPredictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 27, 2026
HLA-B*15:21 carrier status is a susceptibility factor of carbamazepine-induced nonimmediate cutaneous adverse reactions in HLA-B*15:02-negative patients: A retrospective cohort study.

|Jun 19, 2024
Molecular identification of HLA-B75 serotype markers by qPCR: A more inclusive pharmacogenetic approach before carbamazepine prescription.

Kanoot Jaruthamsophon, Pornsiri Sangmanee, Oradawan Plong-On

|Apr 19, 2023
Characterization of Drug-Specific CD4+ T-Cells Reveals Possible Roles of HLA Class II in the Pathogenesis of Carbamazepine Hypersensitivity Reactions.

Kanoot Jaruthamsophon, Paul J Thomson, Sean Hammond

|Dec 27, 2021
No Evidence of Abnormal Expression of Beta-Catenin and Bcl-2 Proteins in Pilomatricoma as One Clinical Feature of Tetrasomy 9p Syndrome.

Chariyawan Charalsawadi, Sasipong Trongnit, Kanoot Jaruthamsophon

|Apr 07, 2021
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.

Ane Ogbe, Barbara Kronsteiner, Donal T Skelly

|May 20, 2016
Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions.

Kanoot Jaruthamsophon, Thanya Sripo, Chonlaphat Sukasem

Pageof 1

Frequent Collaborators

2 joint publications

Areerat Hnoonual

2 joint publications

Oradawan Plong-On

2 joint publications

Chariyawan Charalsawadi

1 joint publications

Jariya Khayman